Norge - norsk - Statens legemiddelverk

teva b.v. - amlodipinbesilat / valsartan - tablett, filmdrasjert - 5 mg / 80 mg

Norge - norsk - Statens legemiddelverk

teva b.v. - amlodipinbesilat / valsartan - tablett, filmdrasjert - 10 mg / 160 mg

Norge - norsk - Statens legemiddelverk

teva b.v. - amlodipinbesilat / valsartan - tablett, filmdrasjert - 5 mg / 160 mg

Norge - norsk - Statens legemiddelverk

baxter medical ab - retinylpalmitat / kolekalsiferol / tokoferol alfa / askorbinsyre / tiamin / riboflavinnatriumfosfathydrat / pyridoksinhydroklorid / cyanokobalamin / folsyre / pantotensyre / biotin / nikotinamid - pulver til injeksjons-/infusjonsvæske, oppløsning - 3500 ie / 220 ie / 11.2 ie / 125 mg / 3.51 mg / 4.14 mg / 4.53 mg / 0.006 mg / 0.414 mg / 17.25 mg / 0.069 mg / 46 mg

Norge - norsk - Statens legemiddelverk

le vet b.v. - fenobarbital - tablett - 50 mg

Norge - norsk - Statens legemiddelverk

le vet b.v. - fenobarbital - tablett - 12.5 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetate - diagnostiske teknikker, endokrine - macimorelin - dette legemidlet er kun til diagnostisk bruk.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Den europeiske union - norsk - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pasienter som har en lav eller svært lav risiko for tilbakefall bør ikke får adjuvant behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. bortsett fra i nydiagnostisert kronisk fase kml, det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer.

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertensjon - agenter som virker på renin-angiotensinsystemet - behandling av essensiell hypertensjon. copalia er indisert hos pasienter hvor blodtrykket ikke er tilstrekkelig kontrollert på amlodipine eller valsartan monoterapi.

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited - amlodipin, valsartan, hydroklortiazid - hypertensjon - angiotensin ii antagonister, kombinasjoner, agenter som handler på renin-angiotensin-systemet, angiotensin ii antagonister og kalsiumantagonister - behandling av essensielle som erstatning terapi i voksen pasienter med blodtrykk er tilstrekkelig kontrollert på en kombinasjon av amlodipine, valsartan og hydroklortiazid (hct), tatt som tre single-komponent formuleringer eller som en dual-komponent og en single-komponent formulering.